Cantabio Pharmaceuticals
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2225 E Bayshore Rd Ste 200, Palo Alto, C...Phone Number
(844) 200-2826Website
www.cantabio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Cantabio Pharmaceuticals
Cantabio is focused on bringing novel, first-in-class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics aimed at addressing the root causes of disease, protein misfolding and oxidative stress. Cantabio's programs focus on protein systems implicated in neurodegenerative disorders, including Alzheimer's and Parkinson's, as well as the effects of oxidative stress and diseases related to this. The company is currently engaged in advanced pre-clinical research into the positive effects of its therapeutic candidates and is focused on developing these towards clinical trials.Explore more
Cantabio Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cantabio Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Cantabio Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Cantabio Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Cantabio Pharmaceuticals launches new products
Check if Cantabio Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Cantabio Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Cantabio Pharmaceuticals
Earning: See what the market has to say on Cantabio Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once Cantabio Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Cantabio Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Cantabio Pharmaceuticals
Compare insights from companies similar to Cantabio Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cantabio Pharmaceuticals
<$5M
11-50
Private
-
2012
AM
Anita MaheswarManager, Research & Business Translation Development
Company Profile Activity
Activity Insights
Cantabio Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cantabio Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cantabio Pharmaceuticals.
Cantabio Pharmaceuticals Tech Stack
A closer look at the technologies used by Cantabio Pharmaceuticals
Cantabio Pharmaceuticals News & Media
Cantabio Pharmaceuticals to Present Latest Positive In Vivo Results From its DJ-1 Targeting Small Molecule Drug Development Program for Parkinson’s Disease at the Milner Therapeutics Symposium at the University of Cambridge, UK
SAN FRANCISCO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals Inc. (OTCQB: CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's (AD), Parkinson's (PD) and other related neurodegenerative diseases, today announced that Dr. Gergely Toth, Cantabio's CEO, will present the latest results from the company's DJ-1 protein targeting small molecule pharmacological chaperone therapeutic program at the Milner Therapeutics Symposium on October 1st 2018.Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Results in a Mice Model of Parkinson’s disease of One of Its Orally Administered Novel DJ-1 Protein Targeting Therapeutic Candidates at the XXV International Symposium on Medicinal Chemistry in Ljubljana, Slovenia
SAN FRANCISCO, July 31, 2018 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals Inc. (OTCQB:CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's (AD), Parkinson's (PD) and other related neurodegenerative diseases, today announced that Dr. Gergely Toth, Cantabio's CEO, will present results from the company's DJ-1 protein targeting small molecule pharmacological chaperone therapeutic program at the XXV International Symposium on Medicinal Chemistry in Ljubljana
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Cantabio Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Cantabio is focused on bringing novel, first-in-class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics aimed at addressing the root causes of disease, protein misfolding and oxidative stress. Cantabio's programs focus on protein syst... Read More
